| Market Cap | ₹8,225Cr |
| ROE | 13.08% |
| P/E Ratio(TTM) | 23.30 |
| EPS(TTM) | 7.79 |
| P/B Ratio | 3.06 |
| Dividend Yield | 0.44% |
| Industry P/E | 33.18 |
| Book Value | 59.32 |
| Debt to Equity | 0.12 |
| Face Value | 1 |
| Parent Organisation | Marksans Pharma Limited |
| Managing Director | Mr. Mark Saldanha |
| NSE Symbol | MARKSANS |
| COMPANY | 52 WEEK | MARKET PRICE | P/E Ratio | |
|---|---|---|---|---|
| Torrent Pharmaceuticals | NA (0.00%) | 59.46 | ||
| Ajanta Pharma | NA (0.00%) | 33.38 | ||
| Gland Pharma | NA (0.00%) | 34.73 | ||
| Eris Lifesciences | NA (0.00%) | 47.12 |